The HCPLive Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.
October 6th 2024
The rheumatology month in review emphasizes new trends in medication use and novel technologies' potential for managing fibromyalgia.
Collaborating Across the Continuum™: The Role of Multidisciplinary Care in the Management of Patients with Exocrine Pancreatic Insufficiency
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
October 16, 2024
Register Now!
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
October 26, 2024
Register Now!
6th Annual Advanced Practice Collaborative
View More
SimulatED™: Personalizing Treatment Choices to Achieve Glycemic and Weight Management Goals
View More
Cases and Conversations™: Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis
November 18, 2024
Register Now!
Shaping the Management of COPD with Biologic Therapy
View More
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Expert Illustrations & Commentaries™: Exploring the Role of Novel Agents for the Management of IgA Nephropathy
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Clinical ShowCase™: Finding the Best Path Forward for Patients with COPD
View More
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
Surv.AI Says™: What Clinicians and Patients Are Saying About Glucose Management in the Technology Age
View More
Clinical ShowCase™: Forming a Personalized Treatment Plan for a Patient With ANCA-Associated Vasculitis
View More
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
Patient, Provider & Caregiver Connection™: Implementing an Effective Management Plan to Improve Outcomes in IgA Nephropathy
View More
Autoantibody Testing Detects SLE and Lupus Nephritis
“Although many different autoantibodies have been investigated in SLE, only a limited number of autoantibodies are being used in clinical practice,” investigators stated. “Due to these limitations, there has been great interest in the discovery of new autoantibodies that can be used in clinical practice.”
Risk Factors Identified for Atherosclerosis and Cardiovascular Events in Women With SLE
Women with systemic lupus erythematosus are more likely to have accelerated progression of atherosclerosis. Recognizing the risk factors, such as larger waist circumference and higher fasting glucose levels, may be an important step in preventing this condition.
Home-Based Exercise Program Improves Quality of Life for Patients With Juvenile Dermatomyositis
“Preliminary evidence has suggested that an exercise training could be effective in improving physical function and quality of life in juvenile dermatomyositis, without exacerbating the disease,” investigators stated.
Upadacitinib Achieved Primary Endpoints in Crohn’s Disease Study
Crohn’s disease inflames the gastrointestinal tract and causes consistent abdominal pain and diarrhea. Upadacitinib (AbbVie), a reversible Janus kinase (JAK) inhibitor, may be able to help patients achieve clinical remission.
AbbVie Updates Upadacitinib Prescription Guidelines Amidst Safety Concerns
Selective Janus kinase (JAK) inhibitor, upadacitinib, is now intended for adults with moderate-to-severe rheumatoid arthritis (RA) who have had inadequate response or intolerance to at least 1 tumor necrosis factor (TNF) blocker.
Rheumatoid Arthritis Quiz: Drug-Free Remission
December 7th 2021Rheumatoid arthritis often requires long-term treatment with disease-modifying antirheumatic drugs (DMARDs), but tapering and even cessation of DMARDs can be considered for patients in remission. Test your knowledge of use of DMARDs in patients in remission with this quiz.
Overdrive Podcast: Impact of COVID-19 on Quality of Life of Patients With Rheumatic Disease
On this month's episode of Overdrive, Rheumatology Network interviewed Courtney Wells, PhD, MPH, MSW, to discuss the impact of COVID-19 on the quality of life of patients with rheumatic conditions, focusing on perceived risk and decision making.